Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.

Abstract:

:One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose therapy (HDT) containing cyclophosphamide, etoposide, carmustine (CVB) and autologous bone marrow transplantation (ABMT). Forty patients were treated while they were in resistant or progressive disease states using alternating MOPP/ABVD protocol; 15 patients received ABMT in first relapse; 51 patients had a complete remission (CR) with first-line therapy but later relapsed and then received conventional salvage therapy; 16 achieved no response or progression ("resistant relapse" patients) and 35 responded partially or completely ("sensitive-relapse" patients). The other 22 patients received ABMT in remission. Following HDT, 56 patients (52.8%) achieved CR and 23 patients (21.6%) achieved a partial remission for an overall response rate of 74.4%. Sixteen patients failed to respond and died in progressive disease 1 to 10 months (median 6 months) after ABMT. High-dose therapy produced severe toxicity including vomiting (100%), mucositis (75%) and liver enzymes and alkaline phosphatase elevations (51%). There were 10 treatment-related deaths. A multivariate analysis identified poor performance status and resistant-relapse patients as very important adverse risk factors for survival immediately after ABMT. These results, while validating this procedure for inducing remissions in advanced highly-treated patients, at the same time confirm the need of employing this approach in first relapse or in second complete remission after standard therapy and before ABMT or, in first complete remission in very high risk Hodgkin's disease patients. Our experience in 15 very poor prognosis Hodgkin's disease patients transplanted in first CR demonstrated to be much significant.

journal_name

Leukemia

journal_title

Leukemia

authors

Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

subject

Has Abstract,Author List Incomplete

pub_date

1991-01-01 00:00:00

pages

68-71

eissn

0887-6924

issn

1476-5551

journal_volume

5 Suppl 1

pub_type

临床试验,杂志文章,多中心研究

相关文献

LEUKEMIA文献大全
  • Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

    abstract::P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.153

    authors: Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

    更新日期:2015-12-01 00:00:00

  • Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.

    abstract::Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is >80%. Outcome in adult ALL is still unsatisfactory, which is due to less cumulative dosing of chemotherapy and less strict adherence to timing of successive cycles. In the present phase II trial, we evaluated a pediatric regimen in...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2011.141

    authors: Rijneveld AW,van der Holt B,Daenen SM,Biemond BJ,de Weerdt O,Muus P,Maertens J,Mattijssen V,Demuynck H,Legdeur MC,Wijermans PW,Wittebol S,Spoelstra FM,Dekker AW,Ossenkoppele GJ,Willemze R,Cornelissen JJ,Dutch-Belgian HO

    更新日期:2011-11-01 00:00:00

  • Selected pharmacologic characteristics of idarubicin and idarubicinol.

    abstract::The pharmacology of ID and IDOL are of interest in light of the potential utility of ID in the treatment of adult and pediatric leukemia patients. Preclinical activity and cellular pharmacology of ID were suggestive of greater clinical activity when compared with several standard anthracyclines. Most intriguing were d...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Ames MM,Spreafico F

    更新日期:1992-01-01 00:00:00

  • Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.

    abstract::The inv(16)(p13q22) chromosomal rearrangement associated with FAB M4Eo acute myeloid leukemia (AML) subtype is characterized by the presence of the CBFbeta/MYH11 fusion transcript that can be used to detect minimal residual disease (MRD). However, qualitative RT-PCR studies of MRD have so far produced conflicting resu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402478

    authors: Guerrasio A,Pilatrino C,De Micheli D,Cilloni D,Serra A,Gottardi E,Parziale A,Marmont F,Diverio D,Divona M,Lo Coco F,Saglio G

    更新日期:2002-06-01 00:00:00

  • Therapeutic targeting of CK2 in acute and chronic leukemias.

    abstract::CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosi...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2017.301

    authors: Buontempo F,McCubrey JA,Orsini E,Ruzzene M,Cappellini A,Lonetti A,Evangelisti C,Chiarini F,Evangelisti C,Barata JT,Martelli AM

    更新日期:2018-01-01 00:00:00

  • Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia.

    abstract::The clinical and laboratory features of 23 patients with a characteristic form of splenic lymphoma with circulating "villous" lymphocytes (SLVL) are described and compared with those of other B cell disorders with preferential splenic involvement. SLVL affects predominantly men in their early 70's and is characterized...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Melo JV,Robinson DS,Gregory C,Catovsky D

    更新日期:1987-04-01 00:00:00

  • A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

    abstract::Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.91

    authors: Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

    更新日期:2008-05-01 00:00:00

  • Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemia.

    abstract::DNA from 76 cases of acute lymphoblastic leukemia (ALL) was tested with a cDNA probe encoding the alpha 2B interferon (IFN) gene transcript. Deletions were found in three of ten pre-B, three of 21 T-cell, four of 22 common and one of 23 null ALL cases. Amongst those with null ALL were 20 infants, most with characteris...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Middleton PG,Prince RA,Williamson IK,Taylor PR,Reid MM,Jackson GH,Katz F,Chessells JM,Proctor SJ

    更新日期:1991-08-01 00:00:00

  • Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.

    abstract::Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0856-3

    authors: Ghasemi R,Struthers H,Wilson ER,Spencer DH

    更新日期:2020-05-12 00:00:00

  • Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.

    abstract::Heterozygous and homozygous deletions of chromosome 13q14.3 are found in 50% of patients with B cell CLL, suggesting the presence of one or more tumour suppressor genes within the deleted region. To identify candidate genes from the region, we constructed a map of 13q14.3 using a combination of genomic and cDNA librar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402551

    authors: Rowntree C,Duke V,Panayiotidis P,Kotsi P,Palmisano GL,Hoffbrand AV,Foroni L

    更新日期:2002-07-01 00:00:00

  • Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.

    abstract::PCR-based detection of minimal residual disease (MRD) in children with precursor B cell acute lymphoblastic leukemia (pre-B ALL) by amplification of clone-specific antigen gene rearrangements has been labor-intensive. In this study we present a simpler, yet accurate, method to assess and quantitate MRD in pediatric pr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401530

    authors: Mayer SP,Giamelli J,Sandoval C,Roach AS,Fevzi Ozkaynak M,Tugal O,Rovera G,Jayabose S

    更新日期:1999-11-01 00:00:00

  • Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.

    abstract::The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.185

    authors: Macor P,Secco E,Mezzaroba N,Zorzet S,Durigutto P,Gaiotto T,De Maso L,Biffi S,Garrovo C,Capolla S,Tripodo C,Gattei V,Marzari R,Tedesco F,Sblattero D

    更新日期:2015-02-01 00:00:00

  • The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line.

    abstract::Chronic exposure to high concentrations of benzene can result in the development of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving high frequency of loss of all or part of chromosomes 5 and/o...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400763

    authors: Stillman WS,Varella-Garcia M,Gruntmeir JJ,Irons RD

    更新日期:1997-09-01 00:00:00

  • Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AML) characterized by the presence of the t(15;17) translocation and the resulting PML/RAR alpha fusion proteins. To date APL is the only AML which is sufficiently sensitive to all-trans retinoic acid (ATRA) differentiating effect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dubois C,Schlageter MH,de Gentile A,Balitrand N,Toubert ME,Krawice I,Fenaux P,Castaigne S,Najean Y,Degos L

    更新日期:1994-10-01 00:00:00

  • Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.

    abstract::Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell ly...

    journal_title:Leukemia

    pub_type: 历史文章,杂志文章,评审

    doi:10.1038/leu.2008.281

    authors: Boerma EG,Siebert R,Kluin PM,Baudis M

    更新日期:2009-02-01 00:00:00

  • Leptin receptor, a surface marker for a subset of highly engrafting long-term functional hematopoietic stem cells.

    abstract::The hematopoietic system is sustained by a rare population of hematopoietic stem cells (HSCs), which emerge during early embryonic development and then reside in the hypoxic niche of the adult bone marrow microenvironment. Although leptin receptor (Lepr)-expressing stromal cells are well-studied as critical regulators...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01079-z

    authors: Trinh T,Ropa J,Aljoufi A,Cooper S,Sinn A,Srour EF,Broxmeyer HE

    更新日期:2020-11-07 00:00:00

  • Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.

    abstract::A relationship was proved between constitutive activity of leukemic cell c-jun-N-terminal kinase (JNK) and treatment failure in AML. Specifically, early treatment failure was predicted by the presence of constitutive JNK activity. The mechanistic origins of this association was sought. A multidrug resistant leukemic c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402457

    authors: Cripe LD,Gelfanov VM,Smith EA,Spigel DR,Phillips CA,Gabig TG,Jung SH,Fyffe J,Hartman AD,Kneebone P,Mercola D,Burgess GS,Boswell HS

    更新日期:2002-05-01 00:00:00

  • KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

    abstract::To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.330

    authors: Clipson A,Wang M,de Leval L,Ashton-Key M,Wotherspoon A,Vassiliou G,Bolli N,Grove C,Moody S,Escudero-Ibarz L,Gundem G,Brugger K,Xue X,Mi E,Bench A,Scott M,Liu H,Follows G,Robles EF,Martinez-Climent JA,Oscier D,Wa

    更新日期:2015-05-01 00:00:00

  • Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

    abstract::Unlike the case with thrombosis, prognostic models for survival and leukemic transformation (LT) in essential thrombocythemia (ET) are not available. Among 605 patients with ET seen at our institution and followed for a median of 84 months, 155 died and LT was documented in 20 patients (3.3%). In a multivariable analy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404500

    authors: Gangat N,Wolanskyj AP,McClure RF,Li CY,Schwager S,Wu W,Tefferi A

    更新日期:2007-02-01 00:00:00

  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

    abstract::In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2014.60

    authors: Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

    更新日期:2014-08-01 00:00:00

  • Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.

    abstract::Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved long non-coding RNA (lncRNA). Overexpression of MALAT1 has been demonstrated to related to poor prognosis of multiple myeloma (MM) patients. Here, we demonstrated that MALAT1 plays important roles in MM DNA repair and cell death. We ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0104-2

    authors: Hu Y,Lin J,Fang H,Fang J,Li C,Chen W,Liu S,Ondrejka S,Gong Z,Reu F,Maciejewski J,Yi Q,Zhao JJ

    更新日期:2018-10-01 00:00:00

  • Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia.

    abstract::We have sought the presence of rearrangements of the immunoglobulin heavy chain gene locus in 13 patients with chronic myeloid leukemia (CML) in lymphoid blastic transformation (L-BT) using the polymerase chain reaction (PCR). The lymphoid nature of the transformation was confirmed by immunophenotyping and/or Southern...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400543

    authors: Spencer A,Vulliamy T,Kaeda J,Goldman JM,Melo JV

    更新日期:1997-02-01 00:00:00

  • Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.

    abstract::The human factor-dependent leukemia cell line UCSD/AML1 contains the t(3;3) (q21;q26) characteristic of the syndrome of acute leukemia with high platelets. The human homologue of the murine leukemia oncogene evi-1 was recently localized to chromosome 3q24-3q28 and transcription of evi-1 is a frequent event in mouse-re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Oval J,Smedsrud M,Taetle R

    更新日期:1992-05-01 00:00:00

  • Treatment and unmet needs in steroid-refractory acute graft-versus-host disease.

    abstract::Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the n...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0804-2

    authors: Malard F,Huang XJ,Sim JPY

    更新日期:2020-05-01 00:00:00

  • Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.

    abstract::Patients with chronic lymphocytic leukemia (CLL) have a high risk of bloodstream infections (BSI). BSI cause significant morbidity and mortality among CLL patients; approximately one-third of fatalities in CLL list infections as cause of death. All CLL patients in Denmark diagnosed between 2008 and 2016 were followed ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0316-5

    authors: Andersen MA,Moser CE,Lundgren J,Niemann CU

    更新日期:2019-03-01 00:00:00

  • Is acute promyelocytic leukemia a curable disease? Treatment strategy for a long-term survival.

    abstract::The major cause of early death in acute promyelocytic leukemia (APL), the high risk of a bleeding diathesis is now successfully counteracted within a few days by differentiation therapy using ATRA. Moreover, no resistance to this drug has been recorded during induction when the usual presence of PML/RAR alpha was conf...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Degos L

    更新日期:1994-01-01 00:00:00

  • Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

    abstract::The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.10

    authors: Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

    更新日期:2013-06-01 00:00:00

  • Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.

    abstract::Monoclonal antibody QBEND10 is reactive with the CD34 antigen in aldehyde-fixed, decalcified, paraffin-embedded bone marrow biopsies. In normal bone marrow it stained endothelial cells lining arterioles and capillaries, sinusoidal (littoral) cells and 0.89% of all haemopoietic cells. QBEND10+ mononuclear cells were se...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Soligo D,Delia D,Oriani A,Cattoretti G,Orazi A,Bertolli V,Quirici N,Deliliers GL

    更新日期:1991-12-01 00:00:00

  • Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes.

    abstract::Human T cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T cell leukemia (ATL) transforms human T cells in vitro and in vivo. Tax, the major transactivator of HTLV-I is critical for the initial events involved in transformation, however, the later steps required for progression from an IL-2 dependent ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gartenhaus RB,Wang P

    更新日期:1995-12-01 00:00:00

  • Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas.

    abstract::Several studies using sensitive in situ hybridization techniques show that, in non-immunocompromised patients, Epstein-Barr virus (EBV) is more frequently detected in lymphomas expressing T cell markers than in B cell lymphomas. Among lymphomas expressing T cell markers, the presence of EBV is highly related to the si...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Kanavaros P,Briere J,Emile JF,Gaulard P

    更新日期:1996-06-01 00:00:00